Market Trends Sanofi misses Q4 top-line and bottom-line estimates; initiates FY25 outlookBy admin8996erT0allJanuary 30, 2025 mohd izzuan Sanofi press release (NASDAQ:SNY): Q4 Non-GAAP EPS of €1.31 misses by €0.05. Revenue of €10.56B (+9.0% Y/Y) misses…
Market Trends Sanofi receives GMP warning letter for Genzyme facilityBy admin8996erT0allJanuary 21, 2025 bankrx The U.S. FDA has issued a warning letter to Sanofi (NASDAQ:SNY) regarding Current Good Manufacturing Practices violations at a…
Market Trends Sanofi reports positive results for subcutaneous Sarclisa (SNY:NASDAQ)By admin8996erT0allJanuary 9, 2025 Panama7Sanofi (NASDAQ:SNY) said that a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment of multiple…
